Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) EBIT: ¥80 Mil (TTM As of Mar. 2026)


SHSE:600613 Shanghai Shenqi Pharmaceutical Investment Management Co Ltd SHSE:600613
53 GF Score
Price ¥4.82
GF Value ¥5.44
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Shanghai Shenqi Pharmaceutical Investment Management Co EBIT?

Shanghai Shenqi Pharmaceutical Investment Management Co SHSE:600613 +0.21% 53 EBIT is ¥80 Mil as of Mar. 2026. GuruFocus rates SHSE:600613 with a GF Score™ of 53/100 and a GF Value™ of ¥5.44 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Shanghai Shenqi Pharmaceutical Investment Management Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥22 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥80 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shanghai Shenqi Pharmaceutical Investment Management Co's annualized ROC % for the quarter that ended in Mar. 2026 was 3.16%. Shanghai Shenqi Pharmaceutical Investment Management Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 7.97%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Shanghai Shenqi Pharmaceutical Investment Management Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 4.17%.

Shanghai Shenqi Pharmaceutical Investment Management Co  (SHSE:600613) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shanghai Shenqi Pharmaceutical Investment Management Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=104.744 * ( 1 - 38.02% )/( (2107.419 + 1997.097)/ 2 )
=64.9203312/2052.258
=3.16 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3145.125 - 333.217 - ( 704.489 - max(0, 620.821 - 1653.92+704.489))
=2107.419

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3044.359 - 332.19 - ( 715.072 - max(0, 605.586 - 1579.204+715.072))
=1997.097

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Shanghai Shenqi Pharmaceutical Investment Management Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=87.124/( ( (1030.856 + max(106.701, 0)) + (1014.009 + max(33.972, 0)) )/ 2 )
=87.124/( ( 1137.557 + 1047.981 )/ 2 )
=87.124/1092.769
=7.97 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(320.807 + 197.499 + 100.633) - (333.217 + 0 + 179.021)
=106.701

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(322.165 + 217.625 + 21.09) - (332.19 + 0 + 194.718)
=33.972

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Shanghai Shenqi Pharmaceutical Investment Management Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=80.087/1921.422
=4.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Shenqi Pharmaceutical Investment Management Co EBIT Related Terms

Shanghai Shenqi Pharmaceutical Investment Management Co EBIT Historical Data

* Premium members only.

The historical data trend for Shanghai Shenqi Pharmaceutical Investment Management Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Shenqi Pharmaceutical Investment Management Co EBIT Chart

Shanghai Shenqi Pharmaceutical Investment Management Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 107.93 80.59 98.17 100.37 80.94

Shanghai Shenqi Pharmaceutical Investment Management Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.64 28.72 20.77 8.81 21.78

SHSE:600613 vs LLY, JNJ, ABBV: EBIT Comparison

For the Drug Manufacturers - General subindustry, Shanghai Shenqi Pharmaceutical Investment Management Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Shenqi Pharmaceutical Investment Management Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Shenqi Pharmaceutical Investment Management Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shanghai Shenqi Pharmaceutical Investment Management Co's EV-to-EBIT falls into.


SHSE:600613
53GF Score
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd SHSE:600613
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Shenqi Pharmaceutical Investment Management Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥80 Mil mean?
Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) has a EBIT of ¥80 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co.
Is Shanghai Shenqi Pharmaceutical Investment Management Co's EBIT too high?
Shanghai Shenqi Pharmaceutical Investment Management Co's current EBIT is ¥80 Mil. Overall, Shanghai Shenqi Pharmaceutical Investment Management Co has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Shenqi Pharmaceutical Investment Management Co's EBIT compare to LLY and JNJ?
Shanghai Shenqi Pharmaceutical Investment Management Co's EBIT of ¥80 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co. Shanghai Shenqi Pharmaceutical Investment Management Co's current EBIT is ¥80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Shenqi Pharmaceutical Investment Management Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.44, compared to a current price of ¥4.82 — trading 11.4% below its estimated fair value. The current EBIT is ¥80 Mil. Shanghai Shenqi Pharmaceutical Investment Management Co's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613), the current EBIT is ¥80 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co stock appears to be undervalued. The current stock price of ¥4.82 is trading 11.4% below its estimated GF Value™ of ¥5.44. GuruFocus considers Shanghai Shenqi Pharmaceutical Investment Management Co to be Modestly Undervalued.

Key valuation signals for SHSE:600613:

  • EBIT: ¥80 Mil
  • GF Value™: ¥5.44 vs. price of ¥4.82 (11.4% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the SHSE:600613 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Shenqi Pharmaceutical Investment Management Co Business Description

Other Exchanges 900904:China
Address 128 Weihai Road, Room 613, Changfa Building, Shanghai, CHN, 200003
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd is mainly engaged in pharmaceutical production and distribution in China.
53GF Score

Get the complete analysis for SHSE:600613

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥4.82
Price
¥5.44
GF Value